CoChat

Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal

Rijal, Komal Raj, Adhikari, Bipin, Ghimire, Prakash, Banjara, Megha Raj, Das Thakur, Garib, Hanboonkunupakarn, Borimas, Imwong, Mallika, Chotivanich, Kesinee, Day, Nicholas P J, White, Nicholas J, Pukrittayakamee, Sasithon · 2019 · The Journal of Infectious Diseases
Cited by 27

The DOI matches its Crossref record.

Abstract

Background: Plasmodium vivax is the main cause of malaria in Nepal. Relapse patterns have not been characterized previously. Methods: Patients with P. vivax malaria were randomized to receive chloroquine (CQ; 25 mg base/kg given over 3 days) alone or together with primaquine (PQ; 0.25 mg base/kg/day for 14 days) and followed intensively for 1 month, then at 1- to 2-month intervals for 1 year. Parasite isolates were genotyped. Results: One hundred and one (49%) patients received CQ and 105 (51%) received CQ + PQ. In the CQ + PQ arm, there were 3 (4.1%) recurrences in the 73 patients who completed 1 year of follow-up compared with 22 of 78 (28.2%) in the CQ-only arm (risk ratio, 0.146 [95% confidence interval, .046–.467]; P < .0001). Microsatellite genotyping showed relatively high P. vivax genetic diversity (mean heterozygosity, 0.843 [range 0.570–0.989] with low multiplicity of infection (mean, 1.05) reflecting a low transmission preelimination setting. Of the 12 genetically homologous relapses, 5 (42%) occurred in a cluster after 9 months, indicating long latency. Conclusions: Although there may be emerging CQ resistance, the combination of CQ and the standard-dose 14-day PQ regimen is highly efficacious in providing radical cure of short- and long-latency P. vivax malaria in Nepal.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/infdis/jiz126

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 39

  1. Ministry of Health and Population, Government of Nepal, 2011, EDCD: Nepal malaria strategic plan 2011–2016 (revised version, December 2011)
  2. Rijal, 2018, Epidemiology of Plasmodium vivax malaria infection in Nepal, Am J Trop Med Hyg, 99, 680, 10.4269/ajtmh.18-0373 · DOI
  3. Howes, 2016, Global epidemiology of Plasmodium vivax, Am J Trop Med Hyg, 95, 15, 10.4269/ajtmh.16-0141 · DOI · Paper page
  4. Battle, 2012, Chapter one–the global public health significance of Plasmodium vivax, 1
  5. White, 2016, Why do some primate malarias relapse, Trends Parasitol, 32, 918, 10.1016/j.pt.2016.08.014 · DOI
  6. Mishra, 2016, Threats to malaria elimination in the Himalayas, Lancet Glob Health, 4, e519, 10.1016/S2214-109X(16)30128-0 · doi:10.1016/s2214-109x(16)30128-0
  7. Ghimire, 2017, Glucose-6-phosphate dehydrogenase deficiency in people living in malaria endemic districts of Nepal, Malar J, 16, 214, 10.1186/s12936-017-1864-2 · DOI · Paper page
  8. World Health Organization (WHO), 2016, Testing for G6PD deficiency for safe use of primaquine in radical care of P. vivax and P. ovale malaria. Policy brief
  9. World Health Organization (WHO), 2015, Guidelines for the treatment of malaria
  10. Rieckmann, 1989, Plasmodium vivax resistance to chloroquine, Lancet, 2, 1183, 10.1016/S0140-6736(89)91792-3 · DOI · Paper page
  11. Collignon, 1991, Chloroquine resistance in Plasmodium vivax, J Infect Dis, 164, 222, 10.1093/infdis/164.1.222 · DOI
  12. Baird, 2004, Chloroquine resistance in Plasmodium vivax, Antimicrob Agents Chemother, 48, 4075, 10.1128/AAC.48.11.4075-4083.2004 · DOI · Paper page
  13. Price, 2014, Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis, Lancet Infect Dis, 14, 982, 10.1016/S1473-3099(14)70855-2 · DOI · Paper page
  14. Yorke, 1925, Further observations on malaria made during the treatment of general paralysis, Trans R Soc Trop Med Hyg, 19, 108, 10.1016/S0035-9203(26)80002-1 · doi:10.1016/s0035-9203(26)80002-1
  15. White, 2011, Determinants of relapse periodicity in Plasmodium vivax malaria, Malar J, 10, 297, 10.1186/1475-2875-10-297 · DOI · Paper page
  16. Hwang, 2013, In vivo efficacy of artemether-lumefantrine and chloroquine against Plasmodium vivax: a randomized open label trial in central Ethiopia, PLoS One, 8, e63433, 10.1371/journal.pone.0063433 · doi:10.1371/journal.pone.0063433
  17. Imwong, 2007, Relapses of Plasmodium vivax infection usually result from activation of heterologous hypnozoites, J Infect Dis, 195, 927, 10.1086/512241 · DOI · Paper page
  18. Chen, 2007, Relapses of Plasmodium vivax infection result from clonal hypnozoites activated at predetermined intervals, J Infect Dis, 195, 934, 10.1086/512242 · DOI · Paper page
  19. Imwong, 2006, Microsatellite variation, repeat array length, and population history of Plasmodium vivax, Mol Biol Evol, 23, 1016, 10.1093/molbev/msj116 · DOI
  20. 2015, National malaria treatment protocol—2015.
  21. Manandhar, 2013, A study on relapse/re-infection rate of Plasmodium vivax malaria and identification of the predominant genotypes of P. vivax in two endemic districts of Nepal, Malar J, 12, 324, 10.1186/1475-2875-12-324 · DOI
  22. Imwong, 2005, Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1, Malaria J, 4, 20, 10.1186/1475-2875-4-20 · DOI · Paper page
  23. Chu, 2018, Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria, Clin Infect Dis, 67, 1543, 10.1093/cid/ciy319 · DOI · Paper page
  24. White, 2002, The assessment of antimalarial drug efficacy, Trends Parasitol, 18, 458, 10.1016/S1471-4922(02)02373-5 · DOI · Paper page
  25. Awab, 2017, Chloroquine-primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial, Am J Trop Med Hyg, 97, 1782, 10.4269/ajtmh.17-0290 · DOI · Paper page
  26. Ganguly, 2013, In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes, Antimicrob Agents Chemother, 57, 1246, 10.1128/AAC.02050-12 · DOI · Paper page
  27. Ganguly, 2014, Recurrence pattern of P. vivax malaria following treatment with chloroquine either alone or in combination with primaquine in urban Kolkata, India, Int J Recent Sci Res, 5, 1046
  28. Kumar, 2016, Therapeutic assessment of primaquine for radical cure of Plasmodium vivax malaria at primary and tertiary care centres in southwestern India, Korean J Parasitol, 54, 733, 10.3347/kjp.2016.54.6.733 · DOI
  29. Saravu, 2016, Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in southwestern India, PLoS One, 11, e0157666, 10.1371/journal.pone.0157666 · DOI · Paper page
  30. Yuan, 2015, Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar, Antimicrob Agents Chemother, 59, 1230, 10.1128/AAC.04270-14 · DOI · Paper page
  31. Kim, 2012, Genotyping of Plasmodium vivax reveals both short and long latency relapse patterns in Kolkata, PLoS One, 7, e39645, 10.1371/journal.pone.0039645 · doi:10.1371/journal.pone.0039645
  32. James, 1936, Clinical and parasitological observations on induced malaria, Proc R Soc Med, 29, 27
  33. Leslie, 2004, Compliance with 14-day primaquine therapy for radical cure of vivax malaria—a randomized placebo-controlled trial comparing unsupervised with supervised treatment, Trans R Soc Trop Med Hyg, 98, 168, 10.1016/S0035-9203(03)00041-5 · DOI · Paper page
  34. Gonzalez-Ceron, 2013, Molecular and epidemiological characterization of Plasmodium vivax recurrent infections in southern Mexico, Parasit Vectors, 6, 109, 10.1186/1756-3305-6-109 · DOI
  35. Commons, 2018, The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a worldwide antimalarial resistance network systematic review and individual patient pooled meta-analysis, Lancet Infect Dis, 18, 1025, 10.1016/S1473-3099(18)30348-7 · DOI · Paper page
  36. Louicharoen, 2009, Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians, Science, 326, 1546, 10.1126/science.1178849 · DOI · Paper page
  37. Adhikari, 2017, Elements of effective community engagement: lessons from a targeted malaria elimination study in Lao PDR (Laos), Glob Health Action, 10, 1366136, 10.1080/16549716.2017.1366136 · DOI
  38. Adhikari, 2016, Community engagement and population coverage in mass anti-malarial administrations: a systematic literature review, Malar J, 15, 523, 10.1186/s12936-016-1593-y · DOI
  39. Taylor, 2018, Estimating the probable cause of recurrence in Plasmodium vivax malaria: relapse, reinfection or recrudescence, BioRxiv

Cited by

See all 27

Metadata

Authors
Rijal, K. R., Adhikari, B., Ghimire, P., Banjara, M. R., Das Thakur, G., Hanboonkunupakarn, B., Imwong, M., Chotivanich, K., Day, N. P. J., White, N. J., & Pukrittayakamee, S.
Venue
The Journal of Infectious Diseases
Published
2019-03-18
Volume
220
Issue
3
Pages
448-456
ISSN
  • 0022-1899
  • 1537-6613
Cited by
27
References
0
Language
en
Funders
  • Mahidol Oxford Research Unit
  • Wellcome Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. https://app.cochat.ai/papers/10.1093/infdis/jiz126
The paper
Rijal, K. R., Adhikari, B., Ghimire, P., Banjara, M. R., Das Thakur, G., Hanboonkunupakarn, B., Imwong, M., Chotivanich, K., Day, N. P. J., White, N. J., & Pukrittayakamee, S. (2019). Efficacy of Primaquine in Preventing Short- and Long-Latency Plasmodium vivax Relapses in Nepal. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiz126

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.